Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dimerix Limited (AU:DXB)
ASX:DXB
Holding AU:DXB?
Track your performance easily
DXB Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.13 - AU$0.67
Previous CloseAU$0.33
Volume228.82K
Average Volume (3M)2.17M
Market Cap
AU$181.30M
Enterprise ValueAU$171.74M
Total Cash (Recent Filing)AU$9.63M
Total Debt (Recent Filing)AU$73.10K
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Mar 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares OutstandingN/A
10 Day Avg. Volume1,620,439
30 Day Avg. Volume2,169,987
Standard Deviation0.34
R-Squared0.00478
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.33Price Target Upside291.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dimerix Limited News
PremiumCompany Announcements
Dimerix’s Phase 3 Kidney Trial Progresses Successfully
PremiumCompany Announcements
Dimerix Gains $7.9 Million Boost for R&D Initiatives
PremiumCompany Announcements
Dimerix’s Webinar Highlights Key FSGS Research Insights
PremiumCompany Announcements
Dimerix Collaborates with NEPTUNE for Trial Recruitment
PremiumCompany Announcements
Dimerix Limited Shows Strong Trial Progress and Financial Growth
PremiumCompany Announcements
Dimerix Announces Key Developments in Kidney Disease TrialsPremiumCompany Announcements
Dimerix Limited Announces Director’s Option Acquisition
PremiumCompany Announcements
Dimerix Limited Issues Unquoted Equity Options for EmployeesOptions Prices
Currently, No data available
---
Ownership Overview
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.13 and its highest was AU$0.67 in the past 12 months.
What is Dimerix Limited’s market cap?
Currently, no data Available
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 03, 2025 which is in 101 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 28, 2024. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Undervalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 557,833,560 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
---
Dimerix Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.33 (291.18% Upside)
AU$1.33 (291.18% Upside)
Blogger Sentiment
Bullish
AU:DXB Sentiment 96%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
124.13%
12-Months-Change
Fundamentals
Return on Equity
-141.42%
Trailing 12-Months
Asset Growth
80.65%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
---
DXB Stock 12 Month Forecast
Average Price Target
AU$1.33
▲(291.18% Upside)
Technical Analysis
Best Analysts Covering DXB
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-26.90%
reiterated a buy rating 2 months ago
Copying Tanushree Jain's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -26.90% per trade.
---